Journal
FRONTIERS IN IMMUNOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.1024333
Keywords
chronic hepatitis B; cytokines; entecavir; hepatitis B e antigen; deoxyribose nucleic acid
Categories
Funding
- High-level Public Health Technical Personnel Training Program of Beijing Municipal Health Commission [2022-3-050]
- Capital Health Research and Development of Special [2022-1-2172]
- Digestive Medical Coordinated Development Center of Beijing Hospitals Authority [XXZ0302, XXT28]
- Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support [XMLX 202127]
- Beijing Science and Technology Commission [Z211100002921059]
- National Science and Technology Major Project of China [2017ZX10201201-001-006, 2017ZX10201201-002-006, 2018ZX10715-005-003-005]
Ask authors/readers for more resources
This study investigated the kinetic changes of serum, virological, and immunological markers during entecavir (ETV) antiviral therapy in HBeAg-positive chronic hepatitis B (CHB) patients. Findings suggest that baseline HBV DNA load, HBeAg, and IL-10 levels were significantly associated with ALT normalization after 48 weeks of ETV treatment.
ObjectiveThe aims of this study were to investigate the kinetic changes of serum, virological, and immunological markers during entecavir (ETV) antiviral therapy and to explore whether these indicators can predict the antiviral efficacy of ETV in hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients. MethodsHBeAg-positive CHB patients were enrolled and treated with ETV 0.5 mg/day. Clinical biochemical, virological, and serological tests were performed at baseline and every 12 weeks during the 48-week treatment. Plasma levels of cytokines (Flt-3L, IFN-alpha 2, IFN-gamma, IL-10, IL-17A, IL-6, TGF-beta 1, TGF-beta 2, TGF-beta 3, and TNF-alpha) were measured at baseline and at 12 and 24 weeks after treatment. Analysis of the trends of these clinical indicators in ETV antiviral therapy was performed. ResultsA total of 105 HBeAg-positive CHB patients were enrolled, and 100 of them completed 48 weeks of ETV treatment and follow-up. After 48 weeks of treatment, hepatitis B s antigen (HBsAg) decline >= 1 log10 was found in seven patients, but no patient achieved HBsAg disappearance. serological HBeAg disappeared in 13 patients, and serological HBeAg transformed in 3 patients. The baseline HBsAg and HBeAg levels, HBV DNA load, IL-10, and TGF-beta 1 levels in the complete virological response group were lower than those in the incomplete virological response group, while the ALT level in the complete virological response group was higher than that in the incomplete virological response group. Both univariate analysis and multivariate analysis showed that baseline biochemical indexes, virological indexes, and cytokine levels had no correlation with the complete virological response at 48 weeks. In multivariate analysis, low baseline HBV DNA load, and HBeAg and IL-10 levels were significantly associated with ALT normalization after 48 weeks of ETV treatment (HBeAg OR = 1.003, 95% CI 1.001-1.006, p = 0.007; HBV DNA OR = 0.184, 95% CI 0.046-0.739, p = 0.017; IL-10 OR = 0.040, 95% CI 0.972-0.999, p = 0.040). ConclusionCytokine levels changed dynamically during ETV antiviral therapy. Low baseline HBV DNA load, and HBeAg and IL-10 levels were significantly associated with ALT normalization after 48 weeks of ETV treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available